SELLAS Life Sciences Group, Inc. (SLS)

Market Cap	2.29B +987.4%
Revenue (ttm)	n/a
Net Income	-32.46M
EPS	-0.21
Shares Out	201.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,655,498
Open	11.50
Previous Close	11.88
Day's Range	11.15 - 11.92
52-Week Range	1.39 - 15.88
Beta	2.57
Analysts	Buy
Price Target	32.50 (+186.6%)
Est. Earnings	Nov 11, 2026

About SLS

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembroli...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 13
• Stock Exchange: Nasdaq
• Ticker Symbol: SLS
• Website: https://sellaslifesciences.com

Analyst Summary

According to 2 analysts, the average rating for SLS stock is "Buy." The 12-month stock price target is $32.5, which is an increase of 186.60% from the latest price.

Price Target

$32.5

(186.60% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 16, 2026

Data Sources Report a data error